Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cyclophosphamide + Fludarabine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cyclophosphamide | Cytoxan | CPM | Chemotherapy - Alkylating 18 | Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary). |
Fludarabine | Fludara | FAMP|Fludarabine phosphate | Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05972720 | Phase II | Cyclophosphamide + Fludarabine CRG-022 | A Phase 2 Study of CRG-022 in Patients With Relapsed/Refractory Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT02774291 | Phase I | Aldesleukin Cyclophosphamide + Fludarabine Filgrastim | Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1 | Terminated | USA | 0 |
NCT04099797 | Phase I | C7R-GD2.CAR-T cells Cyclophosphamide + Fludarabine | C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | Recruiting | USA | 0 |
NCT03049449 | Phase I | Cyclophosphamide + Fludarabine 5F11-28Z CAR-T cells | T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | Completed | USA | 0 |
NCT06026319 | Phase I | CD79b-19 CAR T cells Cyclophosphamide + Fludarabine | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT01701674 | Phase I | Cyclophosphamide + Fludarabine Ipilimumab Aldesleukin | Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts | Active, not recruiting | USA | 0 |
NCT06480565 | Phase Ib/II | ADI-270 Cyclophosphamide + Fludarabine | A Phase 1/2 Trial of ADI-270 in CcRCC | Recruiting | USA | 0 |
NCT06486051 | Phase II | Cyclophosphamide + Fludarabine WZTL-002 | A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma (ENABLE-2) | Recruiting | NZL | 0 |
NCT03089203 | Phase I | CART-PSMA-TGF-beta RDN Cyclophosphamide + Fludarabine | CART-PSMA-TGFbetaRDN Cells for Castrate-Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT06094842 | Phase I | L1CAM-specific CAR+EGFRt+ T cells Bendamustine Cyclophosphamide + Fludarabine | Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer | Not yet recruiting | USA | 0 |
NCT05310591 | Phase Ib/II | Cyclophosphamide + Fludarabine Nivolumab Tisagenlecleucel | Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence (CAPTiRALL) | Recruiting | FRA | 0 |
NCT06191887 | Phase I | Bendamustine BAFFR-CAR T cells Cyclophosphamide + Fludarabine | B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies | Recruiting | USA | 0 |
NCT01256398 | Phase II | Dexamethasone Dasatinib Tacrolimus Cyclophosphamide + Fludarabine Filgrastim Mercaptopurine + Methotrexate + Vincristine Sulfate Melphalan Cytarabine + Daunorubicin + Etoposide Pegfilgrastim Alemtuzumab Leucovorin | Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT03287817 | Phase Ib/II | Pembrolizumab Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells | CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER) | Completed | USA | GBR | 0 |
NCT06415487 | Phase I | Cyclophosphamide + Fludarabine ACE2016 + Pembrolizumab ACE2016 | ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) | Not yet recruiting | USA | 0 |
NCT05702853 | Phase Ib/II | CD19-CD34 CAR transduced T cells Cyclophosphamide + Fludarabine | Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL | Recruiting | USA | 0 |
NCT05963217 | Phase I | Cyclophosphamide + Fludarabine TBI-2001 | Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL | Recruiting | CAN | 0 |
NCT04314843 | Phase Ib/II | axicabtagene ciloleucel + Lenzilumab Cyclophosphamide + Fludarabine | Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19) | Terminated | USA | 0 |
NCT02153580 | Phase I | Etoposide Cyclophosphamide + Fludarabine Bendamustine | Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT03139370 | Phase I | Cyclophosphamide + Fludarabine KITE-718 | Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers | Terminated | USA | 0 |
NCT00167180 | Phase II | Cyclophosphamide + Fludarabine | Post Transplant Donor Lymphocyte Infusion | Terminated | USA | 0 |
NCT05922930 | Phase Ib/II | TROP2-CAR/IL15-transduced CBNK cells Cyclophosphamide + Fludarabine | Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer | Recruiting | USA | 0 |
NCT06447987 | Phase I | Cetuximab Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells Cyclophosphamide + Fludarabine | Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT01853631 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN) | Recruiting | USA | 0 |
NCT04310592 | Phase I | Cyclophosphamide + Fludarabine CYNK-001 | Natural Killer Cell (CYNK-001) Infusions in Adults With AML (CYNK001AML01) | Recruiting | USA | 0 |
NCT06285422 | Phase I | Cyclophosphamide + Fludarabine SC262 | Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) | Recruiting | USA | 0 |
NCT06186401 | Phase I | E-SYNC T cells Cyclophosphamide + Fludarabine | Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells | Recruiting | USA | 0 |
NCT05625594 | Phase I | Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells Cyclophosphamide + Fludarabine | Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma | Recruiting | USA | 0 |
NCT06153251 | Phase I | BMS-986453 Cyclophosphamide + Fludarabine | A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma | Recruiting | USA | FRA | ESP | DEU | 0 |
NCT05478837 | Phase I | Cyclophosphamide + Fludarabine KIND T cells | Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma (PNOC018) | Recruiting | USA | 0 |
NCT05218408 | Phase Ib/II | Cyclophosphamide + Fludarabine CYNK-001 | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type (CYNK001GBM02) | Withdrawn | 0 | |
NCT04196413 | Phase I | Cyclophosphamide + Fludarabine GD2 CAR T cells | GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG) | Recruiting | USA | 0 |
NCT03531736 | Phase I | Rituximab Cyclophosphamide + Fludarabine | T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia | Active, not recruiting | USA | 0 |
NCT05114837 | Phase Ib/II | CAR19-tTreg Cyclophosphamide + Fludarabine | Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL | Withdrawn | USA | 0 |
NCT06096038 | Phase Ib/II | iC9.CAR-CSPG4 T cells Cyclophosphamide + Fludarabine | Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC | Recruiting | USA | 0 |
NCT04103879 | Phase II | ECT-001 cord blood cells Cyclophosphamide + Fludarabine + Thiotepa Tacrolimus Cyclophosphamide + Fludarabine Mycophenolate mofetil | US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia | Active, not recruiting | USA | NLD | 0 |
NCT06205290 | Phase III | Idelalisib + Rituximab Lisocabtagene maraleucel Cyclophosphamide + Fludarabine Bendamustine + Rituximab | A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies | Withdrawn | USA | SWE | NOR | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUT | 0 |
NCT05347485 | Phase II | Ciltacabtagene autoleucel Cyclophosphamide + Fludarabine | A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma | Completed | USA | 0 |
NCT05451849 | Phase Ib/II | Cyclophosphamide + Fludarabine TC-510 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Active, not recruiting | USA | 0 |
NCT04394650 | Phase I | Cyclophosphamide + Fludarabine CC-98633 | A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma | Completed | USA | 0 |
NCT05020678 | Phase I | Cyclophosphamide + Fludarabine NKX019 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | Recruiting | USA | AUS | 0 |
NCT06151847 | Phase II | Cyclophosphamide + Fludarabine Lifileucel Aldesleukin | Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma | Recruiting | USA | 0 |
NCT02830724 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + Anti-hCD70 CAR-T cells | Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | Recruiting | USA | 0 |
NCT03247309 | Phase I | Aldesleukin + IMA201 Cyclophosphamide + Fludarabine | TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) (ACTengine) | Completed | USA | DEU | 0 |
NCT05633615 | Phase II | Cyclophosphamide + Fludarabine axicabtagene ciloleucel + Lisocabtagene maraleucel + Tisagenlecleucel Polatuzumab vedotin-piiq Mosunetuzumab-axgb Mosunetuzumab-axgb + Polatuzumab vedotin-piiq | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05077527 | Phase I | axicabtagene ciloleucel Cyclophosphamide + Fludarabine | Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT06241456 | Phase I | Cetuximab + FT825 Bendamustine + Cisplatin + Docetaxel FT825 Cyclophosphamide + Fludarabine | FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05588440 | Phase Ib/II | Cyclophosphamide + Fludarabine ONCT-808 | A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies | Terminated | USA | 0 |
NCT04323657 | Phase Ib/II | Cyclophosphamide + Fludarabine TC-110 T-cells | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT03704298 | Phase Ib/II | axicabtagene ciloleucel + Utomilumab Cyclophosphamide + Fludarabine | Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma (ZUMA-11) | Terminated | USA | 0 |
NCT04639245 | Phase Ib/II | MAGE-A1-specific TCR cells + unspecified PD-1 antibody Cyclophosphamide + Fludarabine Atezolizumab + MAGE-A1-specific TCR cells MAGE-A1-specific TCR cells | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT03166397 | Phase II | Cyclophosphamide + Fludarabine Aldesleukin Nivolumab tumor infiltrating lymphocytes Ipilimumab | Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients | Recruiting | ISR | 0 |
NCT06305299 | Phase I | Cyclophosphamide + Fludarabine iC9-CAR.B7-H3 T-cells | Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells | Recruiting | USA | 0 |
NCT05495464 | Phase I | Cyclophosphamide + Fludarabine Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine Acalabrutinib + Rituximab | A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | Recruiting | USA | 0 |
NCT03019666 | Phase I | Allogeneic NAM NK cells Cyclophosphamide + Fludarabine | Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | Completed | USA | 0 |
NCT03873805 | Phase I | Cyclophosphamide + Fludarabine Anti-PSCA(dCH2)BBz-CAR-T cells | PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT05989828 | Phase I | Cyclophosphamide + Fludarabine Autologous anti-HLA-A2/NY-ESO-1 TCR T cells | A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer | Not yet recruiting | USA | 0 |
NCT06047977 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin + tumor infiltrating lymphocytes | Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors | Not yet recruiting | USA | 0 |
NCT05883449 | Phase II | AB-101 + AFM13 Aldesleukin Cyclophosphamide + Fludarabine | Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-203) | Recruiting | USA | 0 |
NCT04551885 | Phase I | Cyclophosphamide + Fludarabine Avelumab + FT516 Aldesleukin | FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Terminated | USA | 0 |
NCT02869217 | Phase I | Cyclophosphamide + Fludarabine TBI-1301 | Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | Active, not recruiting | CAN | 0 |
NCT06043713 | Phase I | Bendamustine FHA-11 KRAS G12V-TCR Cyclophosphamide + Fludarabine | Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations | Recruiting | USA | 0 |
NCT03241940 | Phase I | Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells | Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | Recruiting | USA | 0 |
NCT03635632 | Phase I | C7R-GD2.CAR-T cells Cyclophosphamide + Fludarabine | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | Active, not recruiting | USA | 0 |
NCT06236425 | Phase I | Cisplatin + Pembrolizumab Aldesleukin Carboplatin + Fluorouracil + Pembrolizumab TBio-4101 Cyclophosphamide + Fludarabine Cisplatin + Fluorouracil + Pembrolizumab | TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC | Recruiting | USA | 0 |
NCT05681780 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin Nivolumab CD40L-augmented TILs | Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC | Recruiting | USA | 0 |
NCT03081910 | Phase I | CD5 CAR-T cells Cyclophosphamide + Fludarabine | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) | Recruiting | USA | 0 |
NCT05694364 | Phase I | PRGN-3007 Cyclophosphamide Cyclophosphamide + Fludarabine | Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT02905188 | Phase I | GLYCAR T cells Cyclophosphamide + Fludarabine | Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) | Completed | USA | 0 |
NCT03480360 | Phase III | Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | Active, not recruiting | USA | 0 |
NCT02995330 | Phase I | Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Tacrolimus + Testosterone cypionate Cyclophosphamide + Fludarabine | Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer | Terminated | USA | 0 |
NCT03016377 | Phase Ib/II | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL | Recruiting | USA | 0 |
NCT05886491 | Phase Ib/II | Cyclophosphamide + Fludarabine GDX012 | A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT05092451 | Phase Ib/II | CAR.70/IL15-transduced CB-NK cells Cyclophosphamide + Fludarabine | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances | Recruiting | USA | 0 |
NCT06236139 | Phase Ib/II | Cyclophosphamide + Fludarabine Anti-STEAP1 CAR-T cells + Enzalutamide | Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT03913026 | Phase II | ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa | UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia | Active, not recruiting | CAN | 0 |
NCT06481592 | Phase II | Aldesleukin + Lifileucel Cyclophosphamide + Fludarabine | A Study of Lifileucel (tumor-infiltrating Lymphocytes) in Adults with Advanced Endometrial Cancer. | Recruiting | USA | 0 |
NCT06342986 | FT536 Cyclophosphamide + Fludarabine | Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | Recruiting | USA | 0 | |
NCT03938987 | Phase Ib/II | Cyclophosphamide + Fludarabine Anti-CD19 CAR-T cells | Anti-CD19, Dual Co-stimulatory (4-1BB, CD3zeta) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002) | Recruiting | CAN | 0 |
NCT04670068 | Phase I | CAR.B7-H3T cells Cyclophosphamide + Fludarabine | Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian | Recruiting | USA | 0 |
NCT06341647 | Phase I | Cyclophosphamide + Fludarabine AB-201 | Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 | Not yet recruiting | AUS | 0 |
NCT02932956 | Phase I | Cyclophosphamide + Fludarabine Anti-GPC3-scFvGC33-CAR autologous T Lymphocytes | Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (GAP) | Active, not recruiting | USA | 0 |
NCT00338377 | Phase II | Cyclophosphamide + Fludarabine Aldesleukin | Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma | Active, not recruiting | USA | 0 |
NCT05639972 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + E7 TCR T-cells | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | Not yet recruiting | USA | 0 |
NCT06577025 | Phase II | Ciltacabtagene autoleucel Cyclophosphamide + Fludarabine Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Talquetamab-tgvs Daratumumab + Teclistamab | A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma (aMMbition) | Recruiting | USA | BRA | AUS | 0 |
NCT04545762 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT03907852 | Phase Ib/II | Gavocabtagene autoleucel + Ipilimumab + Nivolumab Gavocabtagene autoleucel + Nivolumab Gavocabtagene autoleucel Cyclophosphamide + Fludarabine | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | Active, not recruiting | USA | CAN | 0 |
NCT06615479 | Phase III | Carfilzomib + Daratumumab + Dexamethasone + Lenalidomide BMS-986393 + Carfilzomib + Daratumumab + Dexamethasone + Pomalidomide Cyclophosphamide + Fludarabine | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2) | Not yet recruiting | USA | TUR | SWE | ROU | POL | NOR | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 6 |
NCT06609928 | Phase I | Cyclophosphamide + Fludarabine Anti-FOLR1 CAR-T cells | FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia | Not yet recruiting | USA | 0 |
NCT04074746 | Phase I | Cyclophosphamide + Fludarabine AFM13 | Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas | Active, not recruiting | USA | 0 |
NCT05400109 | Phase I | Cyclophosphamide + Fludarabine UF-KURE19 | Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas | Active, not recruiting | USA | 0 |
NCT06253520 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin + Anti-KRAS G12V TCR cells + GRT-C903 + GRT-R904 Aldesleukin + Anti-KRAS G12D TCR cells + GRT-C903 + GRT-R904 | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | Recruiting | USA | 0 |
NCT04167696 | Phase I | CYAD-02 Cyclophosphamide + Fludarabine | Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1) | Recruiting | USA | BEL | 0 |
NCT04678336 | Phase I | CART123 cells Cyclophosphamide + Fludarabine | CD123 Redirected T Cells for AML in Pediatric Subjects | Recruiting | USA | 0 |
NCT03971799 | Phase Ib/II | Cyclophosphamide + Fludarabine Anti-CD33 CAR-T cells | Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT06500273 | Phase II | ALLO-501A ALLO-647 + Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine | Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL (ALPHA3) | Recruiting | USA | 0 |
NCT05618925 | Phase I | Cyclophosphamide + Fludarabine CD19 t-haNK cells + Rituximab CD19 t-haNK cells + Nogapendekin alfa inbakicept + Rituximab | Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05748197 | Phase I | Cyclophosphamide + Fludarabine ADCLEC.syn1 | A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT06347068 | Phase I | iC9-CAR.B7-H3 T-cells Cyclophosphamide + Fludarabine | Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells | Recruiting | USA | 0 |
NCT06119685 | Phase Ib/II | IDP-023 Cyclophosphamide + Fludarabine Daratumumab + IDP-023 Aldesleukin + IDP-023 IDP-023 + Rituximab | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | Recruiting | USA | 0 |
NCT04160195 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma | Terminated | USA | 0 |
NCT05442515 | Phase Ib/II | CD19/CD22 CAR T cells Cyclophosphamide + Fludarabine | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | Recruiting | USA | 0 |
NCT04848064 | Phase I | Cyclophosphamide + Fludarabine Mogamulizumab | Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma | Recruiting | USA | 0 |
NCT03338972 | Phase I | Cyclophosphamide + Fludarabine Anti-BCMA CAR-T cells | Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma | Completed | USA | 0 |
NCT05714345 | Phase II | Cyclophosphamide + Fludarabine ALLO-647 + Cyclophosphamide + Fludarabine ALLO-501A | Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (EXPAND) | Active, not recruiting | USA | BEL | 0 |
NCT02287311 | Phase I | LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes Cyclophosphamide + Fludarabine | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) | Active, not recruiting | USA | 0 |
NCT05628883 | Phase I | Cyclophosphamide + Fludarabine TBio-4101 Aldesleukin | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | Recruiting | USA | 0 |
NCT05334329 | Phase I | Cyclophosphamide + Fludarabine Atezolizumab TRACK-NK cells | Genetically Engineered Cells (COH06) With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors | Active, not recruiting | USA | 0 |
NCT04526509 | Phase I | Cyclophosphamide + Fludarabine GSK3901961 GSK3845097 | Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors | Terminated | USA | SWE | NLD | DEU | CAN | AUS | 0 |
NCT06364423 | Phase Ib/II | Hu19-CD828Z T cells + Rituximab Cyclophosphamide + Fludarabine | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | 0 |
NCT06043323 | Phase II | axicabtagene ciloleucel Cyclophosphamide + Fludarabine | A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma | Recruiting | USA | 0 |
NCT04614636 | Phase I | Cyclophosphamide + Fludarabine Daratumumab + FT538 Elotuzumab + FT538 FT538 | FT538 in Subjects With Advanced Hematologic Malignancies | Terminated | USA | 0 |
NCT05400122 | Phase I | Aldesleukin + Vactosertib Cyclophosphamide + Fludarabine | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | Recruiting | USA | 0 |
NCT05020015 | Phase II | iC9-CAR.19-IL15-Transduced CB-NK Cyclophosphamide + Fludarabine | A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | Active, not recruiting | USA | 0 |
NCT04714372 | Phase I | Cyclophosphamide + Fludarabine Daratumumab and hyaluronidase-fihj + FT538 | FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia | Completed | USA | 0 |
NCT06237881 | Phase Ib/II | Cyclophosphamide + Fludarabine KSQ-001EX Aldesleukin + KSQ-001EX | A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06066424 | Phase I | Cyclophosphamide + Fludarabine TROP2-CAR/IL15-transduced CBNK cells Rimiducid | Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) | Recruiting | USA | 0 |
NCT05110742 | Phase Ib/II | CAR.5/IL15-transduced CB-NK cells Cyclophosphamide + Fludarabine | Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances | Recruiting | USA | 0 |
NCT03721068 | Phase I | iC9.GD2.CAR.IL-15 T-cells Cyclophosphamide + Fludarabine | Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma | Recruiting | USA | 0 |
NCT00881920 | Phase I | CAR.k.28 cells Cyclophosphamide + Fludarabine | Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL (CHARKALL) | Recruiting | USA | 0 |
NCT06079164 | Phase I | KITE-197 Cyclophosphamide + Fludarabine | Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma | Recruiting | USA | CAN | AUS | 0 |
NCT05032820 | Phase II | Cyclophosphamide + Fludarabine Idecabtagene Vicleucel + Lenalidomide | MM CAR-T to Upgrade Response | Active, not recruiting | USA | 0 |
NCT04088890 | Phase I | Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine | Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies | Active, not recruiting | USA | 0 |
NCT06185751 | Phase I | Cyclophosphamide + Fludarabine WS-CART-CS1 | Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma | Recruiting | USA | 0 |
NCT06045806 | Phase III | Idecabtagene Vicleucel + Lenalidomide Cyclophosphamide + Fludarabine | A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9) | Active, not recruiting | USA | ROU | POL | NOR | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BEL | AUT | AUS | 2 |
NCT01028716 | Phase II | Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Terminated | USA | 0 |
NCT05371093 | Phase III | axicabtagene ciloleucel Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Fludarabine Bendamustine + Rituximab Lenalidomide + Rituximab | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (ZUMA-22) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | 1 |
NCT06190249 | Phase I | Cyclophosphamide + Fludarabine Lifileucel Pembrolizumab Aldesleukin Mesna | Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma | Suspended | USA | 0 |
NCT05949125 | Phase I | Cyclophosphamide + Fludarabine AVC-201 | Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 | Recruiting | NLD | DEU | 0 |
NCT06413498 | Phase III | Cyclophosphamide + Fludarabine Carfilzomib + Daratumumab + Dexamethasone Daratumumab + Dexamethasone + Pomalidomide Bortezomib + Dexamethasone + Pomalidomide CART-ddBCMA Carfilzomib + Dexamethasone | A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3) | Recruiting | USA | 0 |
NCT06128044 | Phase I | CB-012 Cyclophosphamide + Fludarabine | CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AMpLify) | Recruiting | USA | 0 |
NCT03441100 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin IMA202 | TCR-engineered T Cells in NSCLC and HCC Patients | Completed | USA | DEU | 0 |
NCT04245839 | Phase II | Lisocabtagene maraleucel Cyclophosphamide + Fludarabine | A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL) | Recruiting | USA | SWE | ITA | GBR | FRA | ESP | DEU | CAN | AUT | 1 |
NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Terminated | USA | 0 |
NCT05665062 | Phase I | Cyclophosphamide + Fludarabine STK-009 + SYNCAR-001 | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies | Recruiting | USA | 0 |
NCT04088864 | Phase I | Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine | CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies | Active, not recruiting | USA | 0 |
NCT06343376 | Phase I | EGFRt/19-28z/IL-12 CAR-T cells Cyclophosphamide + Fludarabine | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies | Recruiting | USA | 0 |
NCT06064903 | Phase Ib/II | Cyclophosphamide + Fludarabine CD7-CART01 cells | CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL (CD7-CAR01) | Recruiting | ITA | 0 |
NCT06626256 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin + STIL101 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma | Not yet recruiting | USA | 0 |
NCT04892277 | Phase I | Bendamustine IC19/1563 Cyclophosphamide + Fludarabine | CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies | Recruiting | USA | 0 |
NCT05703854 | Phase Ib/II | CAR.70/IL15-transduced CB-NK cells Cyclophosphamide + Fludarabine | Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma | Recruiting | USA | 0 |
NCT05707273 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission | Recruiting | USA | 0 |
NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Recruiting | USA | 0 |
NCT06326463 | Phase I | CD70-CAR-T cells Cyclophosphamide + Fludarabine Mesna | CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies | Recruiting | USA | 0 |
NCT03912831 | Phase I | Cyclophosphamide + Fludarabine KITE-439 | Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers | Terminated | USA | 0 |
NCT03233854 | Phase I | Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells NKTR-255 | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies | Active, not recruiting | USA | 0 |
NCT06358430 | Phase I | Cyclophosphamide + Fludarabine Cetuximab + TROP2-CAR/IL15-transduced CBNK cells | Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) | Not yet recruiting | USA | 0 |
NCT05182073 | Phase I | Cyclophosphamide + Fludarabine FT576 Daratumumab + FT576 | FT576 in Subjects With Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT05672459 | Phase Ib/II | IVS-3001 Cyclophosphamide + Fludarabine | A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors | Recruiting | USA | 0 |
NCT00003553 | Phase II | Cyclophosphamide + Fludarabine Cyclosporine Mycophenolate mofetil Methotrexate | Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer | Completed | USA | 0 |
NCT05418088 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19/CD20/CD22 CAR-T Cells | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies | Recruiting | USA | 0 |
NCT05878184 | Phase I | Cyclophosphamide + Fludarabine SC291 | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | Active, not recruiting | USA | AUS | 0 |
NCT04608487 | Phase I | Cyclophosphamide + Fludarabine axicabtagene ciloleucel | Axi-cel in CNS Lymphoma | Active, not recruiting | USA | 0 |
NCT06598371 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + KSQ-004EX KSQ-004EX | A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors | Recruiting | USA | 0 |
NCT03624036 | Phase Ib/II | Cyclophosphamide + Fludarabine axicabtagene ciloleucel | Safety and Efficacy of KTE-C19 in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia (ZUMA-8) | Terminated | USA | ITA | 0 |
NCT04377932 | Phase I | Cyclophosphamide + Fludarabine AGAR T cells | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | Recruiting | USA | 0 |
NCT05797233 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells | Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies | Active, not recruiting | USA | 0 |
NCT05678205 | Phase Ib/II | AB-201 Cyclophosphamide + Fludarabine | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors | Not yet recruiting | USA | 1 |
NCT04809766 | Phase I | Bendamustine FH-TCR-TMSLN Cyclophosphamide + Fludarabine | Mesothelin-Specific T-Cells (FH-TCR-TMSLN) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT03448393 | Phase I | Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | Recruiting | USA | 0 |
NCT02356159 | Phase Ib/II | Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Methotrexate + Sirolimus + Tacrolimus Doxorubicin + Etoposide + Fludarabine + Vincristine Sulfate Cyclophosphamide + Fludarabine Rituximab | Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | Active, not recruiting | USA | 0 |
NCT03215810 | Phase I | Nivolumab tumor infiltrating lymphocytes Cyclophosphamide + Fludarabine Aldesleukin | Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT05705570 | Phase I | Cyclophosphamide + Fludarabine MB-CART19.1 | A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies (CARTHIAE-1) | Not yet recruiting | BRA | 0 |